In early trading Thursday, the Dow Jones industrials were up 0.25%, the S&P 500 up 0.62% and the Nasdaq up 1.21%.
After U.S. markets closed on Wednesday, Chewy reported better-than-expected earnings per share (EPS) and revenue, primarily due to higher prices for pet food. Sales of non-discretionary pet items rose 18.5%, the company said. Hard-to-please investors want to know where Chewy and its rivals expect to get growth going forward. Shares traded down more than 5% Thursday morning.
KBHome also beat consensus estimates on the top and bottom lines. Deliveries of new homes were down 3% year over year but selling prices rose 2% to an average of $494,500. Fiscal 2023 revenue guidance was in line with expectations. Shares traded up 7% early Thursday.
Before U.S. markets opened on Thursday, Accenture reported EPS and revenue above estimates and issued current quarter guidance in line with consensus estimates. Guidance for fiscal 2023 was above the current estimates. Shares traded up 4%.
Darden Restaurants also beat top-line and bottom-line estimates as overall same-store sales rose nearly 12%. The owner of the Olive Garden and Longhorn Steakhouse chains raised the top end of EPS guidance and the revenue above estimates for the 2023 fiscal year. Shares traded up 0.7%.
General Mills reported sales and profits above expectations and issued upside guidance for full-year EPS and organic net sales. Shares traded up 3.4%.
Here is a preview of what to expect when these two companies report results first thing Monday morning.
BioNTech
Germany-based BioNTech S.E. (NASDAQ: BNTX) and Pfizer developed one of the first COVID-19 vaccines, driving the German company’s share price up by more than 800%. Shares are still up nearly 200% over the past three years since that August 2021 peak. In the past 12 months, however, shares have fallen by about 23.5%.
BioNTech has built a cash pile of nearly $13.2 billion and dropped $200 million of that on a private U.S. firm called OncoC4, developers of a new cancer drug that will have to take on Bristol-Myers Squibb’s Yervoy and AstraZeneca’s Imjudo antibody immunotherapy treatments.
Rival Moderna said Wednesday that it will begin pricing its COVID-19 vaccine at $130 per dose when its federal contracts expire later this year. BioNTech had previously indicated it was considering a price between $110 and $130 per dose. This may just be an opening gambit, but it is not a good look for either Moderna or BioNTech.
Of 16 analysts covering BioNTech, eight have a Hold rating and eight more rate the stock as a Buy or Strong Buy. At a recent price of around $133.70 a share, the upside potential based on a median price target of $213.91 is 60%. At the high target of $302.00, the upside potential is about 126%.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
